Tumour necrosis factor α blockade and the risk of vasculitis
- 1 November 2006
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (11) , 1534-1535
- https://doi.org/10.1136/ard.2006.051888
Abstract
As, in France, the prescription for TNF blockers is limited to the hospitals, all the units using biologicals were contacted. The study included all patients ever known to have developed a vasculitic-like illness when under treatment with TNF blockers, and not only those who developed vasculitis during the 3-month study period.This publication has 9 references indexed in Scilit:
- Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.2005
- Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.2004
- Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.2004
- Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNFα agent etanercept for rheumatoid arthritisJoint Bone Spine, 2004
- Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.2003
- Hypersensitivity Vasculitis with Leukocytoclastic Vasculitis Secondary to InfliximabJournal of Clinical Gastroenterology, 2003
- Anti-tumour necrosis factor therapy associated with cutaneous vasculitisRheumatology, 2002
- Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritisRheumatology, 2002
- Etanercept and infliximab associated with cutaneous vasculitisRheumatology, 2002